Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
source: Cochrane Database of Systematic Reviews
year: 2017
authors: Owusu-Ofori S, Remmington T
summary/abstract:Background:
Acute splenic sequestration crises are a complication of sickle cell disease, with high mortality rates and frequent recurrence in survivors of first attacks. Splenectomy and blood transfusion, with their consequences, are the mainstay of long-term management used in different parts of the world. This is a 2017 update of a Cochrane Review first published in 2002, and previously updated, most recently in 2015.
Objectives:
To assess whether splenectomy (total or partial), to prevent acute splenic sequestration crises in people with sickle cell disease, improved survival and decreased morbidity in people with sickle cell disease, as compared with regular blood transfusions.
Main Results:
No trials of splenectomy for acute splenic sequestration were found.
Author’s conclusion:
Splenectomy, if full, will prevent further sequestration and if partial, may reduce the recurrence of acute splenic sequestration crises. However, there is a lack of evidence from trials showing that splenectomy improves survival and decreases morbidity in people with sickle cell disease. There is a need for a well-designed, adequately-powered, randomized controlled trial to assess the benefits and risks of splenectomy compared to transfusion programmes, as a means of improving survival and decreasing mortality from acute splenic sequestration in people with sickle cell disease.There are no trials included in the review and we have not identified any relevant trials up to August 2017. We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.
DOI: 10.1002/14651858.CD003425.pub4
read more full text
+myBinderRelated Content
-
MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute enter cooperative r...MaxCyte, Inc. today announces it has e...
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
The effects of pain-related anxiety on hypnosis treatment responses in adults with and without sickle cell diseasePain is the most common symptom in sickl...
-
Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer AnnouncesThe Phase 3 RESET trial testing the effe...
-
Randomized Trials Needed to Assess Benefits of Salmonella Vaccines in SCD Patients, Study SaysRandomized controlled trials are needed ...
-
Hospital Playroom Transformed Into Romantic Restaurant For Parents Of Kids With Bone Marrow TransplantsIt was Valentine’s Day with a lot of h...
-
Effects of Rifaximin on Circulating Aged Neutrophils in Sickle Cell DiseaseThere is a large therapeutic gap in sick...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.